Cyclerion Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYCN research report →
About the company
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier.
- CEO
- Regina Graul
- IPO
- 2019
- Employees
- 1
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $14.85M
- P/E
- -2.42
- P/S
- 7.45
- P/B
- 2.12
- EV/EBITDA
- -2.28
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -337.43%
- Net Margin
- -264.73%
- ROE
- -62.10%
- ROIC
- -99.03%
- Revenue
- $2.07M · 3.70%
- Net Income
- $-3,528,000 · -15.41%
- EPS
- $-1.09 · 9.92%
- Op Income
- $-4,973,000
- FCF YoY
- 23.52%
- 52W High
- $8.48
- 52W Low
- $1.03
- 50D MA
- $3.15
- 200D MA
- $2.19
- Beta
- 1.77
- Avg Volume
- 196.72K
Get TickerSpark's AI analysis on CYCN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 7, 25 | CHICKO RHONDA M. | other | 25,000 |
| Mar 25, 25 | Hecht Peter M | other | 181,818 |
| Mar 25, 25 | Higgins Michael J | other | 9,090 |
| Nov 21, 24 | Slate Path Capital LP | sell | 357,880 |
| Aug 5, 24 | Graul Regina Margaret | other | 55,849 |
| Mar 4, 24 | CHICKO RHONDA M. | other | 0 |
| Jan 1, 24 | Hecht Peter M | other | 15,000 |
| Jan 1, 24 | Graul Regina Margaret | other | 50,000 |
| Nov 30, 23 | Katabi Dina | other | 0 |
| Nov 30, 23 | Higgins Michael J | other | 0 |
Our CYCN coverage
Recent articles, reports, and earnings notes.
No research on CYCN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYCN report →Similar companies
Peers in the same neighborhood.